Praxis Precision Medicines, Inc. PRAX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s business segments — net loss?
- Praxis Precision Medicines, Inc. (PRAX) reported business segments — net loss of -$92.56M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s business segments — net loss changed year-over-year?
- Praxis Precision Medicines, Inc.'s business segments — net loss decreased by 33.6% year-over-year, from -$69.3M to -$92.56M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s business segments — net loss?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s business segments — net loss has grown at a 56.8% compound annual growth rate (CAGR), from -$123.28M to -$303.27M.
- What does business segments — net loss mean?
- The total loss generated by the business segment after subtracting all expenses from revenues.
- How do you interpret business segments — net loss?
- A larger loss indicates higher spending on clinical trials or lower revenue, while a smaller loss suggests improved efficiency or increased revenue.
- How does business segments — net loss compare across companies?
- Standard 'Net Income/Loss' metric used by all public companies to measure bottom-line performance.